Date: 2015-09-24
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Servier (France) Nerviano Medical Sciences (Italy)
Product: S 81694 (NMS-P153)
Action
mechanism: kinase inhibitor/inhibitor of the mitotic checkpoint kinase MPS1. MPS1 (also known as TTK) is a conserved kinase which is highly expressed in a number of human tumors of different origin. MPS1 plays a critical role in the control of mitosis. During mitosis, MPS1 is involved in regulation of the spindle assembly checkpoint. The activity of this checkpoint has been shown to be up-regulated in aneuploid tumors, comprising approximately 90% of solid and 70% of hematological cancers. In accelerating mitosis, MPS1 inhibitors have a novel mode of action as compared to currently available drugs targeting this stage of cell division.
Disease: advanced or metastatic solid tumors who have failed previous therapies
Therapeutic area: Cancer - Oncology
Country: Belgium, The Netherlands
Trial details:
Latest
news: * On September 24, 2015, Servier and Nerviano Medical Sciences announced the start of a first in Human clinical trial of the drug S 81694 (NMS-P153), an inhibitor of the mitotic checkpoint kinase MPS1 discovered by Nerviano Medical Sciences and thereafter acquired and further developed by Servier. The study is an open-label, non-randomized, multicenter international trial in patients with advanced or metastatic solid tumors who have failed previous therapies. An initial dose-escalation stage will be followed by expansion in specific solid tumors. The study is designed to confirm the safety and pharmacokinetics of S 81694, administered as a single agent. Secondary objectives include initial assessment of efficacy and determination of the recommended dose for phase 2. Servier is the sponsor of the study, which is being conducted in Belgium and The Netherlands by Nerviano’s clinical affiliate Clioss. S 81694 is supplied by Nerpharma, the CMO affiliate of Nerviano.
